Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 studyMatthew S. Davids, Jennifer R. Brown, Benjamin L. Lampson et al.|The Lancet Oncology|2021Cited by 102
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistanceAishath Naeem, Jennifer R. Brown, Filippo Utro et al.|Blood Advances|2022Cited by 79
Venetoclax plus dose-adjusted R-EPOCH for Richter syndromeMatthew S. Davids, Jennifer R. Brown, Kerry A. Rogers et al.|Blood|2021Cited by 75
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trialMatthew S. Davids, Jennifer R. Brown, Danielle M. Brander et al.|The Lancet Haematology|2019Cited by 72
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S. Davids, Jennifer R. Brown, Christine E. Ryan et al.|Journal of Clinical Oncology|2024Cited by 40